Enviar pesquisa
Carregar
GALT Presentation April 2014
•
1 gostou
•
443 visualizações
R
RedChip Companies, Inc.
Seguir
Saúde
Negócios
Denunciar
Compartilhar
Denunciar
Compartilhar
1 de 35
Baixar agora
Baixar para ler offline
Recomendados
GALT Presentation
GALT Presentation
RedChip Companies, Inc.
Galt 102013
Galt 102013
RedChip Companies, Inc.
Galt
Galt
RedChip Companies, Inc.
Galt march2015
Galt march2015
RedChip Companies, Inc.
Palisade Bio Investor Deck April 2021
Palisade Bio Investor Deck April 2021
RedChip Companies, Inc.
Pathway to the clinic and beyond
Pathway to the clinic and beyond
Critical Outcome Technologies Inc.
Virios Therapeutics Investor 2021
Virios Therapeutics Investor 2021
RedChip Companies, Inc.
Critical Outcome Technologies Business & Scientific Updates
Critical Outcome Technologies Business & Scientific Updates
Critical Outcome Technologies Inc.
Recomendados
GALT Presentation
GALT Presentation
RedChip Companies, Inc.
Galt 102013
Galt 102013
RedChip Companies, Inc.
Galt
Galt
RedChip Companies, Inc.
Galt march2015
Galt march2015
RedChip Companies, Inc.
Palisade Bio Investor Deck April 2021
Palisade Bio Investor Deck April 2021
RedChip Companies, Inc.
Pathway to the clinic and beyond
Pathway to the clinic and beyond
Critical Outcome Technologies Inc.
Virios Therapeutics Investor 2021
Virios Therapeutics Investor 2021
RedChip Companies, Inc.
Critical Outcome Technologies Business & Scientific Updates
Critical Outcome Technologies Business & Scientific Updates
Critical Outcome Technologies Inc.
Corporate Deck - AACR 2020
Corporate Deck - AACR 2020
AsaElmore
Nps pharma jun13pres
Nps pharma jun13pres
Company Spotlight
FDA liaisions
FDA liaisions
IsmailMakanadar
Can-Fite BioPharma - Investor Presentation May 2021
Can-Fite BioPharma - Investor Presentation May 2021
RedChip Companies, Inc.
Indusrty and Fda liasions
Indusrty and Fda liasions
ROHIT
Immuron Corporate Presentation
Immuron Corporate Presentation
RedChip Companies, Inc.
Q3, 2016 earnings slides 9 nov 16
Q3, 2016 earnings slides 9 nov 16
Galenabio
Galena presentation 22 sept 16
Galena presentation 22 sept 16
Galenabio
Sorrento Investor Presentation
Sorrento Investor Presentation
RedChip Companies, Inc.
2016 shareholder meeting presentation final
2016 shareholder meeting presentation final
Galenabio
Cytori corp feb 2016 final
Cytori corp feb 2016 final
cytoriIR
Q9 step4
Q9 step4
Pharmaguideline
Aridis Investor Presentation 2022 Q1
Aridis Investor Presentation 2022 Q1
RedChip Companies, Inc.
Galena presentation 13 sept 16
Galena presentation 13 sept 16
Galenabio
Alternative Approaches to FDA Approval for Drug and Device Firms
Alternative Approaches to FDA Approval for Drug and Device Firms
Michael Swit
Prescription Drug User Fee Act
Prescription Drug User Fee Act
Tarun Kumar Reddy
CATS Redchip Presentation: Global Online Conference August 2017
CATS Redchip Presentation: Global Online Conference August 2017
RedChip Companies, Inc.
FDA & USDA Import Food Safety Forum
FDA & USDA Import Food Safety Forum
TeresaWu
Scythian investor Presentation ppt
Scythian investor Presentation ppt
RedChip Companies, Inc.
Vteq nov 2013-reduced
Vteq nov 2013-reduced
RedChip Companies, Inc.
07 vteq
07 vteq
RedChip Companies, Inc.
Neo stem RedChip's Global Online CEO Conference
Neo stem RedChip's Global Online CEO Conference
RedChip Companies, Inc.
Mais conteúdo relacionado
Mais procurados
Corporate Deck - AACR 2020
Corporate Deck - AACR 2020
AsaElmore
Nps pharma jun13pres
Nps pharma jun13pres
Company Spotlight
FDA liaisions
FDA liaisions
IsmailMakanadar
Can-Fite BioPharma - Investor Presentation May 2021
Can-Fite BioPharma - Investor Presentation May 2021
RedChip Companies, Inc.
Indusrty and Fda liasions
Indusrty and Fda liasions
ROHIT
Immuron Corporate Presentation
Immuron Corporate Presentation
RedChip Companies, Inc.
Q3, 2016 earnings slides 9 nov 16
Q3, 2016 earnings slides 9 nov 16
Galenabio
Galena presentation 22 sept 16
Galena presentation 22 sept 16
Galenabio
Sorrento Investor Presentation
Sorrento Investor Presentation
RedChip Companies, Inc.
2016 shareholder meeting presentation final
2016 shareholder meeting presentation final
Galenabio
Cytori corp feb 2016 final
Cytori corp feb 2016 final
cytoriIR
Q9 step4
Q9 step4
Pharmaguideline
Aridis Investor Presentation 2022 Q1
Aridis Investor Presentation 2022 Q1
RedChip Companies, Inc.
Galena presentation 13 sept 16
Galena presentation 13 sept 16
Galenabio
Alternative Approaches to FDA Approval for Drug and Device Firms
Alternative Approaches to FDA Approval for Drug and Device Firms
Michael Swit
Prescription Drug User Fee Act
Prescription Drug User Fee Act
Tarun Kumar Reddy
CATS Redchip Presentation: Global Online Conference August 2017
CATS Redchip Presentation: Global Online Conference August 2017
RedChip Companies, Inc.
FDA & USDA Import Food Safety Forum
FDA & USDA Import Food Safety Forum
TeresaWu
Scythian investor Presentation ppt
Scythian investor Presentation ppt
RedChip Companies, Inc.
Mais procurados
(19)
Corporate Deck - AACR 2020
Corporate Deck - AACR 2020
Nps pharma jun13pres
Nps pharma jun13pres
FDA liaisions
FDA liaisions
Can-Fite BioPharma - Investor Presentation May 2021
Can-Fite BioPharma - Investor Presentation May 2021
Indusrty and Fda liasions
Indusrty and Fda liasions
Immuron Corporate Presentation
Immuron Corporate Presentation
Q3, 2016 earnings slides 9 nov 16
Q3, 2016 earnings slides 9 nov 16
Galena presentation 22 sept 16
Galena presentation 22 sept 16
Sorrento Investor Presentation
Sorrento Investor Presentation
2016 shareholder meeting presentation final
2016 shareholder meeting presentation final
Cytori corp feb 2016 final
Cytori corp feb 2016 final
Q9 step4
Q9 step4
Aridis Investor Presentation 2022 Q1
Aridis Investor Presentation 2022 Q1
Galena presentation 13 sept 16
Galena presentation 13 sept 16
Alternative Approaches to FDA Approval for Drug and Device Firms
Alternative Approaches to FDA Approval for Drug and Device Firms
Prescription Drug User Fee Act
Prescription Drug User Fee Act
CATS Redchip Presentation: Global Online Conference August 2017
CATS Redchip Presentation: Global Online Conference August 2017
FDA & USDA Import Food Safety Forum
FDA & USDA Import Food Safety Forum
Scythian investor Presentation ppt
Scythian investor Presentation ppt
Destaque
Vteq nov 2013-reduced
Vteq nov 2013-reduced
RedChip Companies, Inc.
07 vteq
07 vteq
RedChip Companies, Inc.
Neo stem RedChip's Global Online CEO Conference
Neo stem RedChip's Global Online CEO Conference
RedChip Companies, Inc.
Dpsi 6262013
Dpsi 6262013
RedChip Companies, Inc.
Efr oct2013
Efr oct2013
RedChip Companies, Inc.
Evsi 6262013
Evsi 6262013
RedChip Companies, Inc.
Cui 6262013
Cui 6262013
RedChip Companies, Inc.
Avth 6262013
Avth 6262013
RedChip Companies, Inc.
08 atnm
08 atnm
RedChip Companies, Inc.
15 thns
15 thns
RedChip Companies, Inc.
02 galt
02 galt
RedChip Companies, Inc.
UUUU Presentation April 2014
UUUU Presentation April 2014
RedChip Companies, Inc.
Nnvc 6262013
Nnvc 6262013
RedChip Companies, Inc.
Uuuu 2014-1 efr-corp_pres(final v.2)
Uuuu 2014-1 efr-corp_pres(final v.2)
RedChip Companies, Inc.
09 qfor
09 qfor
RedChip Companies, Inc.
Glye 102013
Glye 102013
RedChip Companies, Inc.
StarStream Entertainment
StarStream Entertainment
RedChip Companies, Inc.
09 cointree
09 cointree
RedChip Companies, Inc.
Destaque
(18)
Vteq nov 2013-reduced
Vteq nov 2013-reduced
07 vteq
07 vteq
Neo stem RedChip's Global Online CEO Conference
Neo stem RedChip's Global Online CEO Conference
Dpsi 6262013
Dpsi 6262013
Efr oct2013
Efr oct2013
Evsi 6262013
Evsi 6262013
Cui 6262013
Cui 6262013
Avth 6262013
Avth 6262013
08 atnm
08 atnm
15 thns
15 thns
02 galt
02 galt
UUUU Presentation April 2014
UUUU Presentation April 2014
Nnvc 6262013
Nnvc 6262013
Uuuu 2014-1 efr-corp_pres(final v.2)
Uuuu 2014-1 efr-corp_pres(final v.2)
09 qfor
09 qfor
Glye 102013
Glye 102013
StarStream Entertainment
StarStream Entertainment
09 cointree
09 cointree
Semelhante a GALT Presentation April 2014
Galt 5232013
Galt 5232013
RedChip Companies, Inc.
UNCY Unicycive Corporate Presentation- September 2022
UNCY Unicycive Corporate Presentation- September 2022
RedChip Companies, Inc.
UNCY Unicycive Corporate Presentation Final September 2022
UNCY Unicycive Corporate Presentation Final September 2022
RedChip Companies, Inc.
Reata Pharmaceuticals: Creating New Opportunities for Patients
Reata Pharmaceuticals: Creating New Opportunities for Patients
Jon Le Culpepper
Can Fite Investor Presentation August 2022
Can Fite Investor Presentation August 2022
RedChip Companies, Inc.
Clinical Pharmacology: Leveraging Science to Provide Access
Clinical Pharmacology: Leveraging Science to Provide Access
E. Dennis Bashaw
2018/09 – BoA-ML HC Conference
2018/09 – BoA-ML HC Conference
Sanofi
Can Fite Investor Presentation June 2022
Can Fite Investor Presentation June 2022
RedChip Companies, Inc.
Effective Strategies for Successful Global Development
Effective Strategies for Successful Global Development
PAREXEL International
Bellus Health Corporate Presentation May 2016
Bellus Health Corporate Presentation May 2016
BellusHealth
Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...
Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...
Canadian Organization for Rare Disorders
Bellus Health Corporate Presentation June 2016
Bellus Health Corporate Presentation June 2016
BellusHealth
Accelerated clinical trials
Accelerated clinical trials
MrRajanSwamiSwami
Impact of innovative therapies on regulation of therapeutic goods - John Sker...
Impact of innovative therapies on regulation of therapeutic goods - John Sker...
TGA Australia
From biomarkers to diagnostics –the road to success
From biomarkers to diagnostics –the road to success
National Institute of Biologics
2015/07 – IR – Praluent
2015/07 – IR – Praluent
Sanofi
2017 Annual General & Special Meeting of Shareholders
2017 Annual General & Special Meeting of Shareholders
Critical Outcome Technologies Inc.
04 cgix
04 cgix
RedChip Companies, Inc.
Q2, 2016 earnings slides final2
Q2, 2016 earnings slides final2
Galenabio
Q2, 2016 earnings slides final2
Q2, 2016 earnings slides final2
Galenabio
Semelhante a GALT Presentation April 2014
(20)
Galt 5232013
Galt 5232013
UNCY Unicycive Corporate Presentation- September 2022
UNCY Unicycive Corporate Presentation- September 2022
UNCY Unicycive Corporate Presentation Final September 2022
UNCY Unicycive Corporate Presentation Final September 2022
Reata Pharmaceuticals: Creating New Opportunities for Patients
Reata Pharmaceuticals: Creating New Opportunities for Patients
Can Fite Investor Presentation August 2022
Can Fite Investor Presentation August 2022
Clinical Pharmacology: Leveraging Science to Provide Access
Clinical Pharmacology: Leveraging Science to Provide Access
2018/09 – BoA-ML HC Conference
2018/09 – BoA-ML HC Conference
Can Fite Investor Presentation June 2022
Can Fite Investor Presentation June 2022
Effective Strategies for Successful Global Development
Effective Strategies for Successful Global Development
Bellus Health Corporate Presentation May 2016
Bellus Health Corporate Presentation May 2016
Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...
Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...
Bellus Health Corporate Presentation June 2016
Bellus Health Corporate Presentation June 2016
Accelerated clinical trials
Accelerated clinical trials
Impact of innovative therapies on regulation of therapeutic goods - John Sker...
Impact of innovative therapies on regulation of therapeutic goods - John Sker...
From biomarkers to diagnostics –the road to success
From biomarkers to diagnostics –the road to success
2015/07 – IR – Praluent
2015/07 – IR – Praluent
2017 Annual General & Special Meeting of Shareholders
2017 Annual General & Special Meeting of Shareholders
04 cgix
04 cgix
Q2, 2016 earnings slides final2
Q2, 2016 earnings slides final2
Q2, 2016 earnings slides final2
Q2, 2016 earnings slides final2
Mais de RedChip Companies, Inc.
Big North Graphite : Presenting at Global Online CEO Conference Small Stocks...
Big North Graphite : Presenting at Global Online CEO Conference Small Stocks...
RedChip Companies, Inc.
The Coin Tree media kit deck
The Coin Tree media kit deck
RedChip Companies, Inc.
StarStream Entertainment
StarStream Entertainment
RedChip Companies, Inc.
StarStream Entertainment
StarStream Entertainment
RedChip Companies, Inc.
Ir presentation 062314
Ir presentation 062314
RedChip Companies, Inc.
Btcs corporate presentation july 2014 final
Btcs corporate presentation july 2014 final
RedChip Companies, Inc.
Red chip preso 7 11-14
Red chip preso 7 11-14
RedChip Companies, Inc.
Snwv corporate investor presentation - june 2014 - final
Snwv corporate investor presentation - june 2014 - final
RedChip Companies, Inc.
Gbi investor deck_12.04_revised
Gbi investor deck_12.04_revised
RedChip Companies, Inc.
Station digital corporate_road_show_lr_medium v21
Station digital corporate_road_show_lr_medium v21
RedChip Companies, Inc.
DRNE INVESTOR PRESENTATION
DRNE INVESTOR PRESENTATION
RedChip Companies, Inc.
Intercloud Systems: Global Online CEO Conference
Intercloud Systems: Global Online CEO Conference
RedChip Companies, Inc.
Atnm julyconference
Atnm julyconference
RedChip Companies, Inc.
Lightbridge: RedChip's Global Online CEO Conference
Lightbridge: RedChip's Global Online CEO Conference
RedChip Companies, Inc.
Roil: RedChip's Global Online CEO Conference
Roil: RedChip's Global Online CEO Conference
RedChip Companies, Inc.
American water works red_chip's global online ceo conference
American water works red_chip's global online ceo conference
RedChip Companies, Inc.
Exeo: RedChip's Global Online CEO Conference
Exeo: RedChip's Global Online CEO Conference
RedChip Companies, Inc.
Direct Insite: RedChip's Global Online CEO Conference
Direct Insite: RedChip's Global Online CEO Conference
RedChip Companies, Inc.
Lattice: RedChip's Global Online CEO Conference
Lattice: RedChip's Global Online CEO Conference
RedChip Companies, Inc.
QFOR: RedChip's Global Online CEO Conference
QFOR: RedChip's Global Online CEO Conference
RedChip Companies, Inc.
Mais de RedChip Companies, Inc.
(20)
Big North Graphite : Presenting at Global Online CEO Conference Small Stocks...
Big North Graphite : Presenting at Global Online CEO Conference Small Stocks...
The Coin Tree media kit deck
The Coin Tree media kit deck
StarStream Entertainment
StarStream Entertainment
StarStream Entertainment
StarStream Entertainment
Ir presentation 062314
Ir presentation 062314
Btcs corporate presentation july 2014 final
Btcs corporate presentation july 2014 final
Red chip preso 7 11-14
Red chip preso 7 11-14
Snwv corporate investor presentation - june 2014 - final
Snwv corporate investor presentation - june 2014 - final
Gbi investor deck_12.04_revised
Gbi investor deck_12.04_revised
Station digital corporate_road_show_lr_medium v21
Station digital corporate_road_show_lr_medium v21
DRNE INVESTOR PRESENTATION
DRNE INVESTOR PRESENTATION
Intercloud Systems: Global Online CEO Conference
Intercloud Systems: Global Online CEO Conference
Atnm julyconference
Atnm julyconference
Lightbridge: RedChip's Global Online CEO Conference
Lightbridge: RedChip's Global Online CEO Conference
Roil: RedChip's Global Online CEO Conference
Roil: RedChip's Global Online CEO Conference
American water works red_chip's global online ceo conference
American water works red_chip's global online ceo conference
Exeo: RedChip's Global Online CEO Conference
Exeo: RedChip's Global Online CEO Conference
Direct Insite: RedChip's Global Online CEO Conference
Direct Insite: RedChip's Global Online CEO Conference
Lattice: RedChip's Global Online CEO Conference
Lattice: RedChip's Global Online CEO Conference
QFOR: RedChip's Global Online CEO Conference
QFOR: RedChip's Global Online CEO Conference
Último
Russian Call Girls Sadashivanagar | 7001305949 At Low Cost Cash Payment Booking
Russian Call Girls Sadashivanagar | 7001305949 At Low Cost Cash Payment Booking
narwatsonia7
Call Girl Service ITPL - [ Cash on Delivery ] Contact 7001305949 Escorts Service
Call Girl Service ITPL - [ Cash on Delivery ] Contact 7001305949 Escorts Service
narwatsonia7
Call Girls Sawda 9999965857 Cheap and Best with original Photos
Call Girls Sawda 9999965857 Cheap and Best with original Photos
kartikkumark7k7
Hi,Fi Call Girl In Whitefield - [ Cash on Delivery ] Contact 7001305949 Escor...
Hi,Fi Call Girl In Whitefield - [ Cash on Delivery ] Contact 7001305949 Escor...
narwatsonia7
Call Girl Bangalore Aashi 7001305949 Independent Escort Service Bangalore
Call Girl Bangalore Aashi 7001305949 Independent Escort Service Bangalore
narwatsonia7
MVP Health Care City of Schenectady Presentation
MVP Health Care City of Schenectady Presentation
MVP Health Care
Gurgaon Sushant Lok Phase 2 Call Girls Service ( 9873940964 ) unlimited hard...
Gurgaon Sushant Lok Phase 2 Call Girls Service ( 9873940964 ) unlimited hard...
ggsonu500
Disaster Management Cycle (DMC)| Ms. Pooja Sharma , Department of Hospital A...
Disaster Management Cycle (DMC)| Ms. Pooja Sharma , Department of Hospital A...
Era University , Lucknow
Models Call Girls Electronic City | 7001305949 At Low Cost Cash Payment Booking
Models Call Girls Electronic City | 7001305949 At Low Cost Cash Payment Booking
narwatsonia7
FAMILY in sociology for physiotherapists.pptx
FAMILY in sociology for physiotherapists.pptx
Mumux Mirani
Book Call Girls in Hosur - 7001305949 | 24x7 Service Available Near Me
Book Call Girls in Hosur - 7001305949 | 24x7 Service Available Near Me
narwatsonia7
Low Rate Call Girls In Bommanahalli Just Call 7001305949
Low Rate Call Girls In Bommanahalli Just Call 7001305949
ps5894268
2025 Inpatient Prospective Payment System (IPPS) Proposed Rule
2025 Inpatient Prospective Payment System (IPPS) Proposed Rule
Shelby Lewis
Gurgaon Sector 68 Call Girls ( 9873940964 ) Book Hot And Sexy Girls In A Few ...
Gurgaon Sector 68 Call Girls ( 9873940964 ) Book Hot And Sexy Girls In A Few ...
ggsonu500
Call Girls Ghaziabad 9999965857 Cheap and Best with original Photos
Call Girls Ghaziabad 9999965857 Cheap and Best with original Photos
parshadkalavatidevi7
Biology class 12 assignment neet level practise chapter wise
Biology class 12 assignment neet level practise chapter wise
NAGKINGRAPELLY
Russian Escorts Service Delhi 9711199171 SONI VIP & HOT BOOK NOW
Russian Escorts Service Delhi 9711199171 SONI VIP & HOT BOOK NOW
sangeevkumar5478
EMS and Extrication: Coordinating Critical Care
EMS and Extrication: Coordinating Critical Care
Rommie Duckworth
Soft Toric contact lens fitting (NSO).pptx
Soft Toric contact lens fitting (NSO).pptx
Jasmin Modi
Russian Call Girls Ajmeri Gate | 9711199171 | High Profile -New Model -Availa...
Russian Call Girls Ajmeri Gate | 9711199171 | High Profile -New Model -Availa...
sandeepkumar69420
Último
(20)
Russian Call Girls Sadashivanagar | 7001305949 At Low Cost Cash Payment Booking
Russian Call Girls Sadashivanagar | 7001305949 At Low Cost Cash Payment Booking
Call Girl Service ITPL - [ Cash on Delivery ] Contact 7001305949 Escorts Service
Call Girl Service ITPL - [ Cash on Delivery ] Contact 7001305949 Escorts Service
Call Girls Sawda 9999965857 Cheap and Best with original Photos
Call Girls Sawda 9999965857 Cheap and Best with original Photos
Hi,Fi Call Girl In Whitefield - [ Cash on Delivery ] Contact 7001305949 Escor...
Hi,Fi Call Girl In Whitefield - [ Cash on Delivery ] Contact 7001305949 Escor...
Call Girl Bangalore Aashi 7001305949 Independent Escort Service Bangalore
Call Girl Bangalore Aashi 7001305949 Independent Escort Service Bangalore
MVP Health Care City of Schenectady Presentation
MVP Health Care City of Schenectady Presentation
Gurgaon Sushant Lok Phase 2 Call Girls Service ( 9873940964 ) unlimited hard...
Gurgaon Sushant Lok Phase 2 Call Girls Service ( 9873940964 ) unlimited hard...
Disaster Management Cycle (DMC)| Ms. Pooja Sharma , Department of Hospital A...
Disaster Management Cycle (DMC)| Ms. Pooja Sharma , Department of Hospital A...
Models Call Girls Electronic City | 7001305949 At Low Cost Cash Payment Booking
Models Call Girls Electronic City | 7001305949 At Low Cost Cash Payment Booking
FAMILY in sociology for physiotherapists.pptx
FAMILY in sociology for physiotherapists.pptx
Book Call Girls in Hosur - 7001305949 | 24x7 Service Available Near Me
Book Call Girls in Hosur - 7001305949 | 24x7 Service Available Near Me
Low Rate Call Girls In Bommanahalli Just Call 7001305949
Low Rate Call Girls In Bommanahalli Just Call 7001305949
2025 Inpatient Prospective Payment System (IPPS) Proposed Rule
2025 Inpatient Prospective Payment System (IPPS) Proposed Rule
Gurgaon Sector 68 Call Girls ( 9873940964 ) Book Hot And Sexy Girls In A Few ...
Gurgaon Sector 68 Call Girls ( 9873940964 ) Book Hot And Sexy Girls In A Few ...
Call Girls Ghaziabad 9999965857 Cheap and Best with original Photos
Call Girls Ghaziabad 9999965857 Cheap and Best with original Photos
Biology class 12 assignment neet level practise chapter wise
Biology class 12 assignment neet level practise chapter wise
Russian Escorts Service Delhi 9711199171 SONI VIP & HOT BOOK NOW
Russian Escorts Service Delhi 9711199171 SONI VIP & HOT BOOK NOW
EMS and Extrication: Coordinating Critical Care
EMS and Extrication: Coordinating Critical Care
Soft Toric contact lens fitting (NSO).pptx
Soft Toric contact lens fitting (NSO).pptx
Russian Call Girls Ajmeri Gate | 9711199171 | High Profile -New Model -Availa...
Russian Call Girls Ajmeri Gate | 9711199171 | High Profile -New Model -Availa...
GALT Presentation April 2014
1.
Corporate Presentation April 2014 NASDAQ:
GALT www.galectintherapeutics.com © 2014 Galectin Therapeutics NASDAQ:GALT
2.
Forward Looking Statements This
presentation contains, in addition to historical information, statements that look forward in time or that express management’s beliefs, expectations or hopes. Such statements are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as "may," "estimate," "could," "expect" and others. They are based on our current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those described in the statements. These statements include our plans, expectations and goals regarding drugs in development, clinical trials and regulatory approval for any of our drugs or treatments, the anticipated timeline for clinical trials and results, related market opportunities for our drugs, potential benefits of our drugs, efforts related to partnering opportunities with other companies, estimates regarding cash and spending, liquidity and funding requirements for clinical trials, and estimates regarding those impacted by NASH, liver fibrosis and cirrhosis. The risks and uncertainties impacting these statements include that our plans, expectations and goals regarding drugs in development, clinical trials and regulatory approval are subject to factors beyond our control. Our clinical trials may not begin or produce positive results in a timely fashion, if at all, and any necessary changes during the course of such trials could prove time consuming and costly. We may have difficulty in enrolling candidates for testing and we may not be able to achieve the desired results. Upon receipt of regulatory approval for any drug or treatment, we may face competition with other drugs and treatments that are currently approved or those that are currently in development, which could have an adverse impact on our ability to achieve revenues from the approved indication. Plans regarding development, approval and marketing of any of our drugs are subject to change at any time based on the changing needs of our company as determined by management and regulatory agencies. Estimates regarding the potential benefits of our drugs and the potential market for any of our drugs may be inaccurate and, to the extent the estimates are correct, we may not be successful in achieving revenues from any such drugs, as the successful marketing of any approved drugs will be subject to strong competition within the health care industry and patient and physician acceptance of our drugs as safe, affordable and effective. Our ongoing discussions with other companies may not lead to partnering opportunities, and if we are unable to partner with other companies and/ or raise additional capital, we will likely be unable to complete future stages of clinical trials and ultimately produce revenue from our drugs in development. Funding from potential sources of capital, including the potential exercise of warrants, may not materialize. To date, we have incurred operating losses since our inception, and our ability to successfully develop and market drugs may be impacted by our ability to manage costs and finance our continuing operations. For a discussion of additional factors impacting our business, see our most recent Annual Report on Form 10- K and our subsequent filings with the SEC. You should not place undue reliance on forward-looking statements. Although subsequent events may cause our views to change, we disclaim any obligation to update forward-looking statements. 2 © 2014 Galectin Therapeutics NASDAQ:GALT
3.
What We Do •
Clinical stage biopharmaceutical company targeting fibrotic diseases and cancer with novel compounds that inhibit galectin proteins (galectin-3) • Galectin proteins are important in the development and promotion of inflammatory and fibrotic diseases and cancers • Currently in clinical trials in liver fibrosis and cancer • Liver fibrosis indication: NASH (Fatty Liver Disease) with advanced liver fibrosis • Cancer immunotherapy indication: Metastatic melanoma 3 © 2014 Galectin Therapeutics NASDAQ:GALT
4.
Agenda • The Company
and Key Team Members • Galectin Inhibitors • Fibrosis Program – our primary focus • Cancer Immunotherapy • Summary © 2014 Galectin Therapeutics NASDAQ:GALT 4
5.
Experienced Leadership Team 5 James
Czirr, Executive Chairman Peter G. Traber, MD President, CEO, CMO Harold H. Shlevin, PhD COO & Corporate Secretary Jack W. Callicutt CFO Eliezer Zomer, PhD Pharmaceutical Development J. Rex Horton Executive Director, Regulatory Affairs and Quality Assurance © 2014 Galectin Therapeutics NASDAQ:GALT
6.
Key Facts –
As of March 31, 2014 6 Trading Symbol Nasdaq: GALT Corporate Headquarters Norcross, GA (suburb of Atlanta) Stock Price; 52 Week Range $10.80 $3.32 - $19.11 Shares Outstanding 21.9 million Daily Volume (50 day average) 614,000 shares Market Capitalization $335 million Debt $0 Cash & Equivalents $37 million Estimated Spending in 2014 $14.5 million Fiscal Year Ends December 31 Accounting Firm McGladrey LLP © 2014 Galectin Therapeutics NASDAQ:GALT
7.
Agenda • The Company
and Key Team Members • Galectin Inhibitors • Fibrosis Program – our key focus • Cancer Immunotherapy • Summary 7 © 2014 Galectin Therapeutics NASDAQ:GALT
8.
Galectins Inhibitors • Galectin-3
is widely expressed in Fibrosis and Cancer, but highest in immune cells (macrophages) • Under normal physiological situations, galectin-3 is expressed at low levels • In areas of acute or chronic inflammation and fibrogenesis, the gal-3 expression is markedly increased. The majority of cancers express high levels of galectin-3 • Our proprietary drugs are complex carbohydrates with galactose residues that bind galectin proteins (galectin-3 > galectin-1) • Galactomannan (GM) class: GM-CT-01 • Galacto-rhamnogalaturonate (GR) class: GR-MD-02 8 © 2014 Galectin Therapeutics NASDAQ:GALT
9.
Our Pipeline Of
Galectin-3 Inhibitors © 2014 Galectin Therapeutics | NASDAQ:GALT 9 Clinical Focus Stage of Development Drug Indication Discovery Pre-clinical Phase 1 Phase 2 Phase 3 Fibrosis GR-MD-02 Fatty liver disease with advanced fibrosis Lung fibrosis Kidney fibrosis Cancer Immunotherapy GR-MD-02 Melanoma Galectin-3 Inhibitors GR-MD-03 Subcutaneous GR-MD-04 Oral G-XXX* Oral Report on first cohort of Phase 1 Clinical Trial *Galectin Sciences, LLC Timely Reporting: Last bloods: 3-7-14 Last visit: 3-21-14
10.
Intellectual Property • GM-CT
Class (current NCE is GM-CT-01) • US Composition of matter patent issued 2011 (expires 2023) • Five US issued method of use patents in combination with cancer therapy for increased efficacy and reduced side effects • International Patents: 14 granted and 5 pending • Method of use in liver fibrosis issued 2012 (expires 2026) • Multiple method of use patents pending, but all uses covered by composition claims. • GR-MD Class (current NCE is GR-MD-02) • Composition of matter patent pending (priority 2011) • Method of use in liver fibrosis patent issued (expires 2026) • Method of use in NASH patent issued (expires 2031) • Method of use for Cancer Immunotherapy pending (priority 2011) • Method of use in Diabetic nephropathy pending (priority 2011) • Method of use in lung fibrosis pending (priority 2012) 10 Sole ownership of compounds in development © 2014 Galectin Therapeutics NASDAQ:GALT
11.
Agenda • The Company
and Key Team Members • Galectins and Disease • Fibrosis Program – our key focus • Cancer Immunotherapy • Summary 11 © 2014 Galectin Therapeutics NASDAQ:GALT
12.
Liver Fibrosis Development
Program NASH (Non-Alcoholic SteatoHepatitis) • Multiple liver diseases lead to fibrosis • End stage fibrosis, or cirrhosis, leads to liver failure, medical complications, and death • Only current therapy is liver transplant • There is no approved medical therapy for liver fibrosis • Very large unmet medical need 12 © 2014 Galectin Therapeutics NASDAQ:GALT
13.
Very Large Unmet
Medical Need • First indication is fatty liver disease or NASH with advanced fibrosis (non-alcoholic steatohepatitis with fibrosis). • Prevalence of NASH in U.S. is between 9-15 million people • Over 25% will develop cirrhosis; estimated prevalence of patients with advanced fibrosis is 6 million. • NASH cirrhosis projected to be primary reason for liver transplant © 2013 Galectin Therapeutics NASDAQ:GALT 13
14.
NASH with Fibrosis
Development Program: Accomplishments • Phase 1 trial: First cohort All 6 dosed patients saw fibrosis biomarkers decline suggesting regression of fibrosis • Every animal in multiple studies confirmed robust effect on inhibition and regression of fibrosis, as well as reduction in inflammation and cell death in the liver when measured. • GMP drug substance and product produced by CMO • Fast Tract Designation received in August 2013 14 © 2014 Galectin Therapeutics NASDAQ:GALT
15.
GR-MD-02 Is Being
Developed For The Indication Of NASH With Advanced Fibrosis (Stage 3 and 4) 15© 2014 Galectin Therapeutics | NASDAQ:GALT Obesity/Insulin Resistance/Diabetes Steatosis (fatty liver) NASH (inflammation, cell death) Stage 1 2 3 Fibrosis Stage 4 Cirrhosis • No certainty of progression from early to late disease in an individual • Late disease much closer to clinical outcomes • Surrogates of clinical outcomes are better developed for late disease • GR-MD-02 reduces inflammation, ballooning and fat in NASH and reduces existing fibrosis in humans, and reverses cirrhosis in animal models Early Disease Late Disease Clinical Outcomes Complications Transplant Death Targeting Late Disease
16.
All Chronic Liver
Diseases Lead To Fibrosis Example: Liver Fibrosis In Fatty Liver Disease (NASH) © 2014 Galectin Therapeutics | NASDAQ:GALT 16 Stage 1 Stage 2 Stage 3 Stage 4 Patient Liver biopsy Healthy Fatty Fibrosis Cirrhosis Liver failure Bleeding Encephalopathy Edema Asymptomatic Only therapy for patients with cirrhosis is liver transplantation Bridging Fibrosis CirrhosisPortal/CentralPericellular/Central (High Mag) Blue=fibrosis Occurs over decades
17.
Phase 1 Clinical
Trial Of GR-MD-02 In NASH With Advanced Fibrosis: Report On Cohort 1 © 2014 Galectin Therapeutics | NASDAQ:GALT 17 0 28 35 42 56 70Day Infusion -1 Biomarkers Biomarkers Patient inclusion: Biopsy proven NASH with advanced fibrosis (stage 3) Design: Cohort has 8 patients (6 active, 2 placebo, blinded) Dose: Starting dose of 2 mg/kg lean body weight (equivalent to 80 mg/m2); Infusions at days 0, 28, 35 and 42. Primary endpoints: Safety Pharmacokinetics Secondary endpoints: Disease-related serum biomarkers to assess for potential treatment effect
18.
Assessment Methods for
Liver Fibrosis © 2014 Galectin Therapeutics | NASDAQ:GALT 18 Functional metabolic and shunt tests (eg. HepQuant™) Labeled substrate WHVP FHVP Time (s) Pressure(mmHg) Vibrator Probe Ribs Transducter Serum markers Liver biopsy Transient Elastography (FibroScan™) Hepatic venous pressure gradient (HVPG) Source: Nat Rev Gastroenterol Hepatol. 2010 Aug;7(8):425-36.Epub 2010 Jun 29. MR-Elastography • Potential serious complications • 1/50,000th of liver • High sampling variability • 41% discordance of 1 fibrosis stage in NASH* *Ratziu, et al. Gastro. 2005
19.
Serum Biomarkers Of
Fibrosis In NASH © 2014 Galectin Therapeutics | NASDAQ:GALT 19 Composite Scores FibroTest™ (FibroSURE™) • Indirect biomarker of fibrosis • Age and gender, Alpha-2- macroglobulin, Haptoglobin, Apolipoprotein A1, GGTP, Total bilirubin Individual Markers Exploratory* • TGF-β • Lumican • Osteopontin • Matrix Metalloproteinases ELF (Enhanced Liver Fibrosis) Score • Direct biomarker of fibrosis • Hyaluronic acid • TIMP1 (tissue inhibitor of metalloproteinase-1) • P3NP (amino terminal propeptide of type III pro- collagen) Hyaluronic Acid • Matrix polysaccharide • Direct marker • Correlates to fibrosis * Indicates that there is some evidence that suggests they are increased in fibrosis, but not confirmed in sufficient number of patients or studies For more information and references on biomarkers: http://bit.ly/1jzFK50
20.
FibroTest™ (FibroSURE™) Scores Significantly
Decreased In GR-MD-02 Treated Patients © 2014 Galectin Therapeutics | NASDAQ:GALT 20 Equivalent to a 10% change on scale **One patient on GR-MD-02 had scores < 0.08 which was highly discordant with biopsy (stage 3). Patient had high haptoglobin which is known for false negative test. FibroTest™ has been shown to: • Correlate with stage of fibrosis • Assess fibrosis regression • Assess fibrosis progression • Predict liver-related mortality Note: While the numbers are small, exploratory statistics have been performed to evaluate differences using a one-sided t-test and confirmed using a non-parametric test, Mann-Whitney
21.
ELF Score Tended
To Decrease In GR-MD-02 Treated Patients © 2014 Galectin Therapeutics | NASDAQ:GALT 21 7.7 9.8 Severe Fibrosis Moderate Fibrosis Mild/No Fibrosis 10.1 8.8 11.5 *Siemens Diagnostics Equivalent to a 0.5 change on scale ELF score has been shown to: • Correlate with stage of fibrosis • Assess progression (0.032 increase/yr in PBC) • Predict mortality (a one unit change in score correlates to a 2-fold change in liver related mortality)
22.
22 Phase 1 Clinical
Trial • Dose: Starting dose of 2 mg/kg which is within the presumptive therapeutic range; next two cohort doses 4 mg/kg and 8 mg/kg. • Primary endpoints: • Patient safety (Cohort 1 deemed safe at 2mg/kg) • Pharmacokinetics • Secondary endpoints: • Exploratory serum biomarkers to assess for potential treatment effect including markers for inflammation, cell death, and fibrogenesis. Adding FibroScan to cohort 2. Considering adding HepQuant • Timing of expected data from each cohort • Cohort 1: Reported April 1, 2014 Had BioMarker Indicated Fibrosis Reduction • Cohort 2: Jul-Aug 2014 - 4mg/kg dosing • Cohort 3: Oct–Nov 2014 - 8mg/kg dosing © 2014 Galectin Therapeutics NASDAQ:GALT
23.
Fundamental Science on
Target is Strong: Galectin-3 is critically important in the development of organ fibrosis • Galectin-3 null mice (no galectin-3) are resistant to fibrosis due to toxin-induced liver toxicity • Galectin-3 null mice are also resistant to fibrosis in: • Fatty liver disease • Kidney fibrotic disease • Lung fibrotic disease 23 Normal mouse No gal-3 mouseRed stain is collagen, the principal component of fibrotic tissue Henderson, et al 2006 Mice treated with liver toxin to induce fibrosis Normal mice develop fibrosis whereas those without gal-3 do not © 2014 Galectin Therapeutics NASDAQ:GALT
24.
Potential Use in
Lung Fibrosis: GR-MD-02 Reduces Fibrosis in Mouse Model 24 Vehicle Normal GR-MD-02 Marked reduction in area and severity of fibrosis without aggregation into larger formations Large areas of confluent fibrosis. Lung fibrosis induced by tracheal instillation of bleomycin followed by four infusions of either vehicle or GR-MD-02 © 2014 Galectin Therapeutics NASDAQ:GALT
25.
Potential Use in
Kidney Fibrosis: GR-MD-02 Reduces Fibrosis in Diabetic Mouse 25 Vehicle Normal GR-MD-02 Reduction in interstitial fibrosis Arrows show areas of interstitial fibrosis © 2014 Galectin Therapeutics NASDAQ:GALT
26.
26 Phase 2 Clinical
Trial Plans • Patient inclusion: Biopsy proven NASH with advanced fibrosis (stage 3 and stage 4 with well compensated cirrhosis) • Design: Randomized, placebo controlled, and double blind. • Dose: Likely two dosage groups • Treatment Duration: 4-12 months TBD • Primary endpoint: Liver biopsy: Collagen proportional area • FDA-AASLD NASH endpoints workshop September 5-6, 2013 • Galectin human NASH biopsy study done to guide design • Timeline: Start around end of 2014; Top line data: End 2015-1H 2016. • Secondary endpoints: • Liver Biopsy: NASH Activity Score and Fibrosis Stage • Liver function testing: HepQuant (bile acid clearance test) • Imaging methods—Fibroscan or MR-elastography • Serum biomarkers based on analysis of Phase 1 data: ELF Score key biomarker © 2014 Galectin Therapeutics NASDAQ:GALT
27.
Fibrosis Strategy Summary •
NASH with Advanced Fibrosis: Evidence of efficacy of GR-MD-02 from well controlled phase 2 clinical trial • Other Organ Fibrosis: Potential for partnering opportunities • Lung fibrosis – pre-clinical results suggest possible use in Idiopathic Pulmonary Fibrosis • Kidney fibrosis • Ongoing discussions with large pharmaceutical companies • Discussions will provide foundation for partnering opportunities at the most opportune time 27 © 2014 Galectin Therapeutics NASDAQ:GALT
28.
Competition in NASH •
Most drugs in development focus on improving NASH activity score (fat, inflammation, and cell death) at a stage of the disease when there are minimal amounts of fibrosis. • PIVENS • FLINT trial (NIDDK and Intercept) • Few companies currently have programs focused on fibrosis which is the key cause of liver failure in patients • Galectin: GR-MD-02 • Gilead: Lysyl oxidase-like-2 mAb (GS-6624): Monoclonal antibody that blocks the enzyme which cross links collagen fibers • Initiated Phase 2 trials in 2012 in patients with NASH and fibrosis • Top line data Q3 2015 28 © 2014 Galectin Therapeutics NASDAQ:GALT
29.
Summary of Findings •
GR-MD-02 was safe and well tolerated at 2 mg/kg (80 mg/m2) with no drug- related adverse events • Pharmacokinetics was consistent between individuals and after single and multiple doses; exposure was 40% of lowest dose used in NASH animal model; this was a therapeutic dose • Key composite biomarkers of fibrosis improved after four doses of GR-MD-02 • Key inflammatory cytokines were decreased after four doses of GR-MD-02 • Patients with greater cellular injury as indicated by elevated ALT levels, had a marked decrease in CK-18, a cell death biomarker In addition to being safe and well tolerated, GR-MD-02 improved biomarkers of fibrosis, inflammation and liver cell injury in patients with NASH with advanced fibrosis 29 © 2014 Galectin Therapeutics | NASDAQ:GALT
30.
Agenda • The Company
and Key Team Members • Galectin Inhibitors • Fibrosis Program – our key focus • Cancer Immunotherapy • Summary 30 © 2014 Galectin Therapeutics NASDAQ:GALT
31.
Cancer Therapy Strategy •
Focus on cancer immunotherapy based on the hypothesis that galectin inhibitors will enhance efficacy of immunotherapies • Metastatic melanoma is initial cancer indication • In US 76,000 new diagnoses and 9,100 deaths annually • 5% five year survival for metastatic disease • Even with newly approved drugs, still a substantial unmet medical need • We have sought collaborations with institutions that have: • Demonstrated clinical trial expertise in melanoma • Tumor immunology basic science research • Ability to conduct clinical trials and assist in funding • Two collaborations have been established • Ludwig Cancer Institute, Brussels Belgium • Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute (EACRI) Providence-Portland Medical Center, Portland Oregon 31 © 2014 Galectin Therapeutics NASDAQ:GALT
32.
CD8+ T-Cells Cytokines (kill tumor
cells) T-Cells 32 Tumor Cells Potential sites of action for galectin inhibition in tumor immunology Galectin-3 CD8+ T-Cells Clonal Expansion Immunotherapies Checkpoint Inhibitor Blockage: anti-CTLA4 anti-PD1 Tumor Vaccines Potential for galectin inhibitors to enhance anti-tumor immune response Potential for galectin inhibitors to enhance anti-tumor activity of T-cells by blocking “Galectin Effect” Galectin-3+ © 2014 Galectin Therapeutics NASDAQ:GALT
33.
Pre-clinical studies show
galectin inhibitors enhance immune response • Collaboration established in 2012 with Earle A. Chiles Research Institute (EACRI) • Pre-clinical results demonstrate that treatment with GR-MD-02 enhances antigen-specific CD8+ T-cell response and augmentation of memory CD8+ T-cells in non-tumor mice • In tumor bearing animals, the combination of checkpoint inhibitors (anti-CTLA4 and anti-PD1) with GR-MD-02 enhances CD8+ and CD4+ T-cell proliferation, reduces tumor size, and enhances survival in multiple mouse cancer models • These results have led to decision to initiate a clinical trial combining Yervoy with GR-MD-02 33 © 2014 Galectin Therapeutics NASDAQ:GALT
34.
Checkpoint inhibitor blockage
plus GR-MD-02 boosts anti-tumor immunity in syngeneic mouse models of prostate and breast cancer 34 *p<0.05 aCTLA-4 = anti-CTLA-4 mAb [ipilimumab in humans (Yervoy, BMS)] aPD-1 = anti-PD-1 mAb [positive results in clinical trials, BMS, Merck] Unpublished data 2013: Stefanie N. Linch, Melissa J. Kasiewicz, Peter G. Traber, and William L. Redmond © 2014 Galectin Therapeutics NASDAQ:GALT
35.
© 2013 Galectin
Therapeutics NASDAQ:GALT 35 Thank You
Baixar agora